



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# IncuCyte® NeuroLight Red Lentivirus—Synapsin Promoter

Catalog number: 4584

## Contents

- 1x vial of IncuCyte® NeuroLight Red Lentivirus - Synapsin promoter (0.45 mL/vial)

## Storage and stability

The NeuroLight Red lentivirus reagent should be stored at  $-80^{\circ}\text{C}$ . Avoid repeated freeze-thaw cycles. Lentivirus is stable for at least 3 months from date of receipt when stored at  $-80^{\circ}\text{C}$ .

## Test size

Material supplied is sufficient for 1 x 96-well plate.

## Product description

NeuroLight Red is a lentiviral based live-cell neuronal labeling reagent driven by a synapsin promoter, resulting in the long term expression of red fluorescent protein (mKate2) in neuronal cell bodies and neurites. NeuroLight Red ensures highly-efficient, yet non-disruptive labeling of primary or iPSC-derived neurons over days and weeks, and enables the kinetic quantification of neurite length and branching in the presence of astrocytes and other non-neuronal cell types

such as microglia.

The IncuCyte® NeuroLight Red Lentivirus reagent has been validated for use with the IncuCyte® Live-Cell Analysis System and can be used alongside the IncuCyte® Annexin V Green or IncuCyte® Cytotox Green Reagents for multiplexed measurements of apoptosis and cytotoxicity.

## Virus Description

3rd generation HIV-based, VSV-G pseudotyped lentiviral particles encoding a red fluorescent protein (mKate2).

- Promoter: Synapsin
- Spectral Properties: Ex (max): 588 nm; Em (max): 633 nm


Third generation lentiviral-based vectors are commonly used to transfer genetic information to cells for gene therapy and/or research purposes. The Essen BioScience IncuCyte® NeuroLight Red lentiviral-based reagent has been specially

designed to efficiently transduce multiple neuronal cell types with low toxicity. The NeuroLight Red lentivirus encodes a red fluorescent protein driven off a synapsin promoter to strengthen neuronal expression and minimize non-neuronal crossover. Our extensive validation experiments have shown that expression of this red fluorescent protein does not negatively alter functional cell biology (e.g. morphology, neurite outgrowth, and neurite branching) of neurons in co-culture with astrocytes. In combination, the IncuCyte® Live-Cell Analysis System and NeuroLight Red Reagent provide an integrated solution for kinetically measuring neurite dynamics *in vitro*.


## Example data

**NOTE:** This product is designed for use in a neuronal co-culture assay format. Performance in a mono culture format has not been validated.

IncuCyte images of the IncuCyte® NeuroPrime rCortical Neurons in co-culture with rat astrocytes.



Phase-contrast/fluorescent blended image showing forebrain neurons infected with NeuroLight Red. Scale bar: 100 $\mu\text{m}$ .



Fluorescent image of rCortical neurons expressing NeuroLight Red, same field of view as image on left. Scale bar: 100 $\mu\text{m}$ .

## Protocols: IncuCyte® NeuroLight Red Lentivirus

### Materials required but not provided


#### Software

- IncuCyte® Live-Cell Analysis System with IncuCyte® NeuroTrack Software Module (Cat.# 9600-0010)

#### Reagents

- 5-Fluoro-2'-deoxyuridine – Sigma Aldrich (Cat. No. F0503)
- Uridine – Sigma Aldrich (Cat. No. U3003)
- Surface coating materials for 96 well plate

### Protocol Overview: IncuCyte® NeuroPrime Red Cell and Reagent Kit



**CRITICAL:** Use rigorous aseptic technique at all times.  
Only open the culture plate and medium bottles within a tissue culture hood.

### Protocol: Neuronal co-culture

- 1) Plate neurons at desired density and on matrix of choice in a 96-well plate and incubate at room temperature for 30 minutes. Place in incubator and allow 2-4 hours for cells to adhere.
  - 2) Add appropriately diluted NeuroLight Red Reagent to achieve desired concentration. The final well volume should be 200  $\mu$ L per well.  
**NOTE:** Quality control for the IncuCyte NeuroLight Red Reagent is the ability to efficiently infect IncuCyte rCortical Neurons to express mKate2, driven off of the synapsin promotor of the IncuCyte NeuroLight Red Lentivirus, such that a volume of > 3.2  $\mu$ L/20,000 neurons results in a neurite length of > 50  $\mu$ m/mm<sup>2</sup> in a neurite outgrowth assay (rCortical Neurons/rAstrocytes co-culture experiment). We recommend performing a volumetric titration from 100-0.14  $\mu$ L for each neuronal cell line evaluated. The lowest concentration that results in the highest neurite outgrowth measurement should be selected. Evaluation of neurite dynamics is to be performed on an IncuCyte Live-Cell Analysis System.
  - 3) Incubate the 96-well plate at 37° C for 16-24 hours.
  - 4) Remove 190  $\mu$ L transduction media and add 140  $\mu$ L/well of appropriate neuronal medium.
  - 5) Initiate co-culture by plating 50  $\mu$ L of astrocytes on top of the infected neurons. We recommend seeding astrocytes at 15,000 – 20,000 viable cells/well, whether astrocyte suspension is prepared from fresh stocks or cryopreserved cells.
  - 6) Place plate in the incubator, on a microplate tray in the vIncuCyte® system imaging system, to initiate assay.
  - 7) Approximately 48 hours post-plating astrocytes, remove 100  $\mu$ L of media from each well and replace with 100  $\mu$ L fresh media containing 2x concentrations of 5-Fluoro-2'-deoxyuridine and uridine to a final assay concentration of 8  $\mu$ g/mL and 28  $\mu$ g/mL, respectively, in order to arrest astrocyte proliferation.
  - 8) Monitor the cultures over the next 5-12 days, performing a 50% media change every third day.
- Transduction efficiencies of 60-70% are typical. In some cases, it may be preferred to use a lower MOI in order to track neurite dynamics in a high density culture.

#### Related Products:

Catalog # 4585 IncuCyte® NeuroPrime Red Cell and Reagent Kit  
Catalog # 4586 IncuCyte® rAstrocytes

Catalog # 4753 IncuCyte® rCortical Neurons  
Catalog # 9600-0010 IncuCyte® NeuroTrack Software Module

## Safety Considerations

The backbone of the Lentivirus particles in this system has been modified to improve their safety and minimize their relation to the wild-type, human HIV-1 virus. These modifications include:

- The lentiviral particles are replication-incompetent and only carry the non-oncogenic gene of interest.
- A deletion in the 3' LTR (U3) resulting in "self-inactivation" (SIN) of the Lentivirus after transduction and genomic integration of the target cell (Yee et al., 1987; Yu et al., 1986; Zufferey et al., 1998). This alteration renders the lentiviral genome incapable of producing package able virus following host integration.
- The envelope is pseudotyped with the VSV-G gene from Vesicular Stomatitis Virus of the HIV-1 envelope (Burns et al., 1993; Emi et al., 1991; Yee et al., 1994).

Replication-defective lentiviral vectors, such as the 3rd generation vector provided in this product, are not known to cause any diseases in humans or animals. However, lentivirus particles still pose some biohazardous risk because they can transduce primary human cells and can integrate into the host cell genome thus posing some risk of insertional mutagenesis. For this reason, **we highly recommend that you treat lentiviral stocks as Biosafety**

## Biohazard Note

The NeuroLight Red lentivirus contain 3rd generation HIV-based, VSV-G lentiviral particles. The lentiviral particles are replication-incompetent and only carry the non-oncogenic gene of interest. Further, a deletion in the 3' LTR (U3) results in "self-inactivation" (SIN) of the Lentivirus after transduction and genomic integration of the target cell (Yee et al., 1987; Yu et al., 1986; Zufferey et al., 1998). This alteration renders the lentiviral genome incapable of producing packageable virus following host integration. Finally,

**Level 2 (BSL-2, BL-2) organisms and strictly follow all published BL-2 guidelines with proper waste decontamination.**

For more information about the BL-2 guidelines and Lentivirus handling, we recommend referring to local documentation based on geography. The Essen BioScience 3rd generation HIV-based lentivirus' meet BL-2 requirements based on the criteria in the document, "Biosafety in Microbiological and Biomedical Laboratories", 5th Edition, published by the Centers for Disease Control (CDC).

This document may be downloaded at

<http://www.cdc.gov/biosafety/publications/bmb15/index.htm>

**Institutional Guidelines:** Safety requirements for use and handling of lentiviruses may vary at individual institutions.

We recommend consulting your institution's health and safety guidelines and/or officers prior to implementing the use of these reagents in your experiments.

A detailed discussion of lentiviral vectors is provided in Pauwels, K. et al (2009). State-of-the-art lentiviral vectors for research use: Risk assessment and biosafety recommendations. *Curr. Gene Ther.* 9: 459-474.

the envelope is pseudotyped with the VSV-G gene from Vesicular Stomatitis Virus place of the HIV-1 envelope (Burns et al., 1993; Emi et al., 1991; Yee et al., 1994). Although the virus tests negative for mycoplasma, bacteria and fungi, no test procedure can guarantee the absence of known and unknown infectious agents. Consequently, all products should always be considered potentially biohazardous and appropriate precautions should be taken. Use good laboratory practice and aseptic technique at all times.

**FOR RESEARCH USE ONLY. NOT FOR THERAPEUTIC OR DIAGNOSTIC USE.**

## Licences and warranty

Essen BioScience warrants that this product performs as described on the product label and in all literature associated with the sale of said product when used in accordance with the described protocol. This limited warranty is the sole warranty. No other warranties exist that extend beyond this warranty, either expressed or implied. Essen BioScience disclaims any implied warranty of merchantability or warranty of fitness for a particular purpose. Essen BioScience disclaims any responsibility for injury or damage and shall not be liable for any proximate, incidental or consequential damages in connection with this product.

If it is proven to the satisfaction of Essen BioScience that this product fails to meet performance specifications, Essen BioScience's sole obligation, at the option of Essen BioScience, is to replace the product or provide the purchaser with credit at or below the original purchase price. This limited warranty does not extend to anyone other than the purchaser. Notice of suboptimal performance must be made to Essen BioScience within 30 days of receipt of the product.

This Essen BioScience product contain proprietary nucleic acid(s) coding for proprietary fluorescent protein(s) being, including its derivatives or modifications, the subject of pending patent applications and/or patents owned by Evrogen JSC (hereinafter "Evrogen Fluorescent Proteins").

The purchase of Essen BioScience products incorporating these fluorescent proteins conveys to the buyer the non-transferable right to use Evrogen Fluorescent Proteins only for research conducted by the buyer. No rights are conveyed to modify or clone the gene encoding fluorescent protein contained in this product or to use Evrogen Fluorescent Proteins for commercial purposes. The right to use Evrogen Fluorescent Proteins specifically excludes the right to validate or screen compounds for commercial purposes. For information on commercial licensing, contact Evrogen Licensing Department, email: [license@evrogen.com](mailto:license@evrogen.com).